Markets
PFE

Glaxo's Encouraging Asthma & HIV Data at Medical Meetings

An image of people surrounding a sheet of paper with many charts on it
Credit: Shutterstock photo

GlaxoSmithKline plcGSK announced data from a study, showing that patients whose asthma was uncontrolled with Xolair witnessed improved asthma control on switching to Glaxo's new respiratory medicine, Nucala.

The OSMO study evaluated if severe asthma patients, whose disease was uncontrolled despite taking Novartis NVS /Roche's RHHBY asthma medicine Xolair for an average of 2.5 years, saw better asthma control following a switch to Nucala. Data presented from the study showed that following the Nucala switch, these eligible patients experienced fewer symptoms, better lung function, improved asthma-related quality of life and fewer exacerbations. The data, which contributes to the extensive body of evidence for Nucala, were presented by Glaxo at American Academy of Allergy, Asthma & Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in Orlando.

Nucala, approved to treat severe eosinophilic asthma, is one of the key new products in Glaxo's respiratory portfolio, which is driving the top line.

In a separate press release, Glaxo and partner Pfizer, Inc.'s PFE HIV-focused company, ViiV Healthcare, announced 24-week, interim data from the phase IIIb INSPIRING study, evaluating the safety and efficacy of investigational candidate dolutegravir in antiretroviral treatment-naive (ART-naïve) adults with HIV, co-infected with tuberculosis (TB).

Data from the study showed that 81% of HIV/TB co-infected adults (on a rifampin-based TB treatment), who were administered dolutegravir (50mg twice-daily) in combination with two nucleoside reverse transcriptase inhibitors (NRTI) therapies, maintained viral suppression. In the group of patients who received efavirenz (600mg once-daily) with two NRTIs, 89% maintained viral suppression. The data were presented at the annual conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

According to the company's press release, tuberculosis accounts for around one in three AIDS-related deaths. There are many complications related to concurrent treatment of TB and HIV. The INSPIRING data supports the use of dolutegravir in HIV/TB co-infected patients.

Glaxo's shares have risen 3.7% this year so far, outperforming the 1.7% decrease witnessed by the industry .

Glaxo has a Zacks Rank #2 (Buy). You can see .

Glaxo has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Wall Street's Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Roche Holding AG (RHHBY): Free Stock Analysis Report

Pfizer Inc. (PFE): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

GlaxoSmithKline PLC (GSK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PFE GSK RHHBY NVS

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More